Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Re-irradiation combined with cetuximab for locally recurrent or secondary squamous cell carcinoma of the head and neck
2007-004280-22Phase 2Terminated
- Sponsor
- Universitätsklinikum Schleswig-Holstein, Campus Lübeck: Klinik für Strahlentherapie
- Start
- May 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab in head and neck squamous cell carcinoma (HNSCC), sponsored by Universitätsklinikum Schleswig-Holstein, Campus Lübeck: Klinik für Strahlentherapie. Primary endpoint: Feasibility rate of cetuximab in combination with re-irradiation. Started May 2010; status: terminated.
02
Drugs
cetuximab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2007-004280-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004280-22.